Laidlaw & Company LTD may not be a household name in investment advice, investment banking, and finance but the “boutique” investment company headed by Chief Executive Officer Matthew Eitner and Managing Partner and Head of Capital Markets James P. Ahern is well known to institutional and private investors with deep pockets. The company boasts a 170 history of investment management, investment banking, and solid growth for their clients.
The primary focus of Laidlaw & Company LTD is primarily health care, wealth management, and alternative investments. The company is structured in a way that makes each division a separate entity that functions much like a separate company.
The design allows more fluidity in strategy and also produces protection from the fluctuations in each division harming other parts of the organization and their client’s holdings.
The emphasis on health care includes new and advanced technologies, therapeutics, and emerging treatments that are based on genetics. The Affordable Care Act has made medicine a more lucrative investment target and Laidlaw & Company has taken full advantage of the government incentives that spur new discoveries that quickly turn profitable.
Alternative investments at Laidlaw & Company mean emerging technologies including new methods of airline booking, social media alternatives, sports marketing, and internet marketing. The more than $200 million invested in 13 new ventures since 2010 are expected to begin showing larger returns in the near future.
Laidlaw & Company LTD originated in Britain and is now an established firm in New York City. The firm is licensed to manage assets for investors in the United States and Britain.
Calculated risk in health care and technology has thus far produced a healthy return on investment for the clients of Laidlaw & Company.